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As genome sequencing moves from the realm of research and 
difficult-to-solve clinical cases into routine clinical care, so do 
the wider implications of this technology. In patients or fami-
lies with a suspected genetic disorder for which single-gene or 
panel testing fails to provide a genetic explanation, genome 
sequencing is becoming widely available. Whole-genome 
sequencing (WGS) and whole-exome sequencing (WES)—
wherein the genome or the protein-coding parts of the genome 
are sequenced in its entirety—might completely replace panel 
tests in the foreseeable future.
Although WES and WGS provide a valuable opportunity to 
learn about genomic contributions to disease (“primary” find-
ings), they also have the potential to reveal genetic informa-
tion that may not pertain to the patient’s presenting condition, 
including variants associated with other health conditions, 
which may or may not be medically actionable and are unex-
pected.1 A variety of terms have been applied to such findings 
(“secondary,” “incidental,” “additional”);2–4 the term secondary 
findings (SF) has gained traction and is used here inclusively to 
cover findings that are not pertinent to the presenting condi-
tion, whether detected incidentally or actively sought.
The issue of SF management in WES/WGS has sparked 
much debate. SF are not new to medicine, but they are becom-
ing a more frequent issue in genetics owing to more extensive 
use of WES/WGS in the diagnosis of rare disease and cancer. 
With each human genome expected to contain approximately 
100 genuine loss-of-function variants,5 SF in WES/WGS are 
inevitable. Full disclosure of SF is economically and logistically 
impractical, but it has been argued that complete nondisclosure 
is unethical due to the potential benefits of medical interven-
tion for some SF.6 Current practice in research and clinical set-
tings varies between the two extremes. In 2013, the American 
College of Medical Genetics and Genomics (ACMG) put for-
ward recommendations concerning SF in clinical WES/WGS: 
active screening of a defined list of genes, in which mutations 
could imply risk of potentially life-threatening disease, where 
intervention is available, and in which a long asymptomatic 
phase may conceal disease expression.7 The ACMG report sug-
gested that in all individuals undergoing clinical WES/WGS, 
there is a moral obligation to report variants of known (or in 
some cases expected) pathogenicity and to interpret them in the 
context of the patient’s personal and family history. Although 
Submitted 21 April 2016; accepted 17 June 2016; advance online publication 1 September 2016. doi:10.1038/gim.2016.109
Purpose: As whole-exome sequencing (WES) and whole-genome 
sequencing (WGS) move into routine clinical practice, it is timely to 
review data that might inform the debate regarding secondary find-
ings (SF) and the development of policies that maximize participant 
benefit.
Methods: We systematically searched for qualitative and quantitative 
studies that explored stakeholder views on SF in WES/WGS. Frame-
work analysis was undertaken to identify major themes.
Results: Forty-four articles reporting the views of 11,566 stakehold-
ers were included. Stakeholders were broadly supportive of returning 
“actionable” findings, but definitions of actionability varied. Stake-
holder views on SF disclosure exist along a spectrum: potential WES/
WGS recipients’ views were largely influenced by a sense of rights, 
whereas views of genomics professionals were informed by a sense 
of professional responsibility. Experience with genetic illness and 
testing resulted in greater caution about SF, suggesting that truly 
informed decisions require an understanding of the implications and 
limitations of WES/WGS and possible findings.
Conclusion: This review suggests that bidirectional interaction dur-
ing consent might best facilitate informed decision making about SF 
and that dynamic forms of consent, allowing for changing prefer-
ences, should be considered. Research exploring views from wider 
perspectives and from recipients who have received SF is critical if 
evidence-based policies are to be achieved.
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there is support for the ACMG recommendations, opponents 
(and alternative guidelines from Europe and Canada) argue for 
greater caution in the analysis and return of such findings.8–12
As WES and WGS begin to be implemented in routine clini-
cal practice, such as through the 100,000 Genomes Project 
currently under way in the UK National Health Service, 
increasing numbers of patients and their healthy relatives are 
being recruited. It is therefore timely to collect and review data 
that might inform this debate so that WES and WGS initiatives 
maximize clinical utility and contribute to ethical health-care 
delivery.
Commentators have argued that the development of policy 
around SF needs to consider the views and attitudes of relevant 
stakeholders and to obtain insights into the factors that have 
contributed to their formulation.13 Since the publication of a 
systematic review on secondary findings in genomics 4 years 
ago,14 which urgently called for research in this area, many 
empirical studies have been conducted. Due to the contem-
poraneous collection of these empirical data, SF management 
policies in WES/WGS have inevitably been unable to make full 
use of them. To date, we are aware of no systematic review of 
these studies; therefore, we have collated and synthesized them 
to evaluate the extent to which they might inform policy on 
secondary findings and to identify areas for further research.
MAteRiALS And MetHOdS
Literature search strategy
We conducted a systematic search for research studies that 
examined views and preferences toward SF in WES/WGS. 
The protocol for this review was prospectively registered in an 
online database.15 Searches were conducted across six databases 
and included all literature in the databases from their date of 
inception to April 2015, with electronic updates included 
through 1 May 2016 (Figure 1). Search terms for secondary 
findings (including incidental and additional) were combined 
with terms for clinical sequencing (genetic, genomic, genome, 
and exome sequencing) (Supplementary Table S1 online).
Study selection criteria
The review included primary research articles based on qualita-
tive (semi-structured interview-based and focus group-based) 
and quantitative (survey-based and questionnaire-based) 
methods. Studies were included if they explored stakeholder 
views and experiences regarding SF in WES/WGS in a health-
care context in both clinical and research settings. Articles were 
excluded if they were not published in English or if the citation 
lacked an abstract. Articles were also excluded if they did not 
discuss WES/WGS (e.g., discussion limited to chromosomal 
microarray) or if they did not include (or only included super-
ficial) discussion of secondary findings. Articles that explored 
views on return of results in a non–health care context, such 
as direct-to-consumer genetic testing, were also excluded. 
Secondary findings specifically for minors are not discussed 
because we acknowledge that this raises additional issues and 
could warrant their own review.
Two authors (M.P.M., E.O.) independently screened the titles 
and abstracts of all identified articles against the eligibility cri-
teria using Covidence systematic review management software 
(http://covidence.org). In cases of disagreement, inclusion was 
resolved at a meeting between the two reviewers. Both review-
ers then screened full-text copies of the selected articles to 
determine final inclusion. Initial screening was followed by 
reference scanning and snowballing, where the references of 
included works were searched manually to find additional arti-
cles relevant to the review.
data extraction and analysis
For both qualitative and quantitative studies, a general data 
extraction form was used that included bibliographic informa-
tion, study characteristics, participant characteristics, and main 
findings. Two authors (M.P.M., B.F.) independently completed 
the data extraction for each study and one (M.P.M.) checked for 
accuracy and completeness.
A framework analysis approach was used16 whereby data inte-
gration occurred at the point of extraction. The approach was 
well-suited for this review because it can be applied to mixed 
methods studies and is particularly useful for multidisciplinary 
health research teams.17 Although traditionally applied to pri-
mary data, we used it as a review methodology. This was feasi-
ble because the studies investigate the same topics in a manner 
that can be categorized together.17
Initially, M.P.M. and E.O. reviewed six articles (three qualita-
tive and three quantitative studies). The results sections of the 
qualitative studies were coded in a nonrestrictive manner and 
combined with analysis of questions asked across quantitative 
studies in order to produce a working analytical framework. 
Figure 1  Study selection process.
Records identified from initial search:
PubMed
n = 179
Web of
science
n = 235
SCOPUS
n = 239
Electronic search outputs merged and stored in EndNote
n = 873
Articles considered relevant, proceeded to title and abstract review
n = 416
Total articles considered relevant,
proceeded to full text review
n = 57
Additional articles included
on the basis of ‘Snowballing’
n = 3
Total number of articles included
n = 44
Title and abstract review
excluded (n = 359)
Nonhuman, no WGS/WES, no (or superficial)
discussion of IF, irrelevant; non primary research
(reviews); wrong methodology (clinical,
laboratory); policy/guidelines, legal, ethics
Full text review
Excluded (n = 16)
No views on incidental findings provided; wrong
aims (health economics); analysis inappropriate
based on methods
Duplicates removed
n = 457
Medline/
PsychINFO
n = 208
Philosopher’s
index
n = 8
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This framework was applied to all of the other studies in which 
the results sections were coded (by M.P.M.) using NVivo 
10 (QSR International) and manually reviewed (by E.O.). 
Throughout this process, the authors continued to revise the 
framework to reflect the data most accurately. Articles included 
from electronic updates were each coded (by M.P.M. and E.O.) 
and integrated into the preexisting framework. Data from 
the final framework were compared and evaluated to derive 
a higher-order synthesis that goes beyond the content of the 
included articles.
Critical appraisal
Each of the studies was assessed using an established quality 
appraisal system, with a particular emphasis on assessing the 
comprehensiveness of reporting. In the case of the qualita-
tive studies we used the COREQ checklist tool,18 which was 
adapted using the Critical Appraisal Skills Programme checklist 
(Supplementary Table S2 online).19,20 In the case of the quan-
titative studies, we used a checklist tool adapted from Boynton 
and Greenhalgh21 and Greenhalgh et al. (Supplementary 
Table  S3 online).22 In both cases, two authors (M.P.M. and 
B.F.) independently scored articles according to the appropriate 
checklist after piloting three by consensus. Interassessor reli-
ability was measured by calculating κ statistics. No quality cut-
off was used, but a set of initial screening questions was used to 
ensure appropriateness of methodology and analysis and rel-
evance to synthesis topic .
ReSULtS
Systematic review
A total of 44 published research studies met the criteria for 
inclusion (Supplementary Table S7 online). Of the included 
articles, 15 used quantitative methods, 25 used qualitative 
methods, and 4 used mixed methods (Table 1). The majority of 
the studies (72.7%) were from the United States, with the others 
representing Canadian (13.6%), European (9.1%), and multina-
tional (4.5%) groups of stakeholders.
Study participants
Accounting for studies reporting on the same participants, 
the viewpoints of 11,566 unique stakeholders are represented 
(Table 1). Stakeholders include patients with genetic disorders 
or cancer diagnosis, relatives, WES/WGS research participants 
and members of the public (collectively termed “WES/WGS 
recipients”); health-care professionals (HCPs) in genetics or 
other specialties, both patient-facing and health-care scientists, 
primary care physicians, genetics researchers, and institutional 
review board chairs (“WES/WGS providers”). Both of these 
groups include actual and potential recipients or providers 
of WES/WGS. Participants have a wide range of exposure to 
genetic disease and genetic testing, from potentially no direct 
exposure (members of the public) to those who are actively pro-
viding or receiving WES/WGS; 34.1% of studies include par-
ticipants who have “direct WES/WGS experience” (providing 
or receiving) together with participants who do not (Table 1). 
No studies in the review focus on stakeholder experiences with 
handling or receipt of genomic SF.
Critical appraisal
Across the studies, quality and comprehensiveness of reporting 
were highly variable (Supplementary Tables S4 and S5 online): 
table 1 Demographics of included studies
Category n %
Study type
Quantitative 15 56.8
Qualitative 25 34.1
Mixed methods 4 9.1
Total 44
Study origin
United States 32 72.7
Canada 6 13.6
Other countries 4 9.1
Belgium 1 2.3
Denmark 1 2.3
Greece 1 2.3
Netherlands 1 2.3
Multinational 2 4.5
Topic of investigationa
Management of secondary findings 28 63.6
Return of results 11 25.0
WGS consent process 8 18.2
WGS, broadly 6 13.6
Participants have direct experience with WES/WGS
Yes 19 43.2
No 10 22.3
Mixed 15 34.1
Stakeholders representedb
Quantitative and mixed methods studies
Genetics health professionals 2,789 25.9
Nongenetics health professionals 1,128 10.5
Researchers 681 6.3
Patients 367 3.4
Research participants 858 8.0
Members of the public 4961 46.0
Total 10,784
Qualitative studies
Genetics health professionals 204 26.2
Nongenetics health professionals 34 4.3
Researchers 55 7.0
Patients 152 19.4
Research participants 129 16.5
IRB chairs 34 4.3
Members of the public 174 22.2
Total 782
aTotal exceeds 100% because some studies were deemed to fall under two primary 
topics of investigation. bParents/relatives of patients and research participants 
included within those groups.
IRB, institutional review board; WES/WGS, whole-exome sequencing or whole-
genome sequencing.
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scores for quantitative papers ranged from 8 to 23 (out of 26), 
whereas scores for qualitative papers ranged from 11 to 19 (out 
of 32). Although reporting of data collection was weak across 
the studies, with few qualitative studies reporting the theory 
underpinning analysis, findings/results were generally well 
reported. Qualitative studies elicited novel concepts and acted 
as particularly rich sources of data for the synthesis. Between 
reviewers, there was substantial agreement on the scores for 
quantitative papers (κ score = 0.614, 95% CI: 0.538, 0.690) and 
qualitative papers (κ score = 0.749, 95% CI: 0.697, 0.781).
thematic areas
From the framework analysis we identified 10 major thematic 
areas (Table 2). Illustrative quotations from the primary stud-
ies can be found in the Supplementary Material and Methods 
(Table S6 online).
Preferences for secondary findings. An overwhelming 
majority of stakeholders believe that some form of SF should 
be returned if identified.23–44 When measured quantitatively, 
studies report a high desire (95–100%) to receive or return 
clinically actionable SF27–29,31–33,38,43,44; notably, this includes 
surveys of genetics HCPs.31,33 The most commonly cited reason 
for wanting SF was to have the opportunity to act on findings, 
although the definition of “actionability” varied. It included the 
availability of treatment13,24,33,36,42,45–48 and prevention,24–26,42 but 
others endorsed or raised issues such as the ability to plan or 
alter lifestyle24,26,27,32,35,41,42,45,49 or influence reproductive decision 
making.25,29,30,32,33,37,45,48,50,51 More than half of stakeholders, to whom 
the question was asked, desired to receive or return “all” secondary 
findings, regardless of actionability (52–100%).25–28,33,38,39,43 Some 
cited knowledge as empowering,25,29,32,41 and many felt a sense of 
entitlement to this information (detailed further under “Rights 
and Responsibility” below). Of note, while some studies reported 
that “all” study participants were interested in receiving some 
form of SF,23,25,29 many reported a small proportion of recipients 
who wanted only primary findings.27,28,31,33,38,41,44 Providers did 
support the return of some SF; however, comparative studies 
found slightly less support for returning SF among genetics 
HCPs compared to nongenetics HCPs,33 and among providers 
with more clinical training.42,52 These are professionals who 
interact directly with patients and might have disclosed, or be 
in a position to disclose, SF. Support for return of SF with less 
certainty (including variants of unknown significance) was 
lower than unambiguously pathogenic variants, but it was still 
present.13,24,29,41,48,50
Impacts and implications.  Inevitably, as a result of the 
emergent use of WES/WGS, discussions of impacts of SF 
disclosure from WES/WGS were largely hypothetical. The most 
commonly cited reason against disclosure was the potential to 
cause anxiety or psychological harm.24,29,34–36,41,43,45,46,49,50,53 This 
theme was widely raised in qualitative studies (Table 1): semi-
structured interview and focus group designs elicited interactive 
and qualified opinions, thus providing greater insights into how 
SF might be construed.30,32,39,40,41,42,46,49,50 In some of these studies, 
participants acknowledged becoming less inclined to desire 
all SF during the course of the interview or focus group.23,39,46 
Although recognized by both WES/WGS providers34,43,49–51,53–55 
and recipients,26,39,41,46,49 potential psychological harms of SF were 
more frequently of concern to providers. Recipients discussed 
the burden of knowing, particularly about disease risk that may 
not affect them for some years, the potential for SF to adversely 
change the way they lived their lives, and incompatibility with 
religious beliefs.30,35,40,41,46 One study found that nearly three-
quarters of participants factored potential distress arising from 
SF into their decision26; however, for most, potential anxiety did 
not override their desire to receive SF.24,34
Stakeholders also raised concerns about overwhelming WES/
WGS recipients with too much information,54 discrimination 
in insurance and employment,24,26,30,32,36,41,56 privacy,23,27,41,44,51,54 
and stigmatization.41,48,50 WES/WGS providers, specifically, 
raised the following additional concerns: justice issues related 
to limited resources,45,48,49,57 complex logistics57,58 strains on 
time and funding,45,48,57–59 lack of participant understand-
ing,48,60 qualification of HCPs to manage SF,48 and the fact that 
knowledge around WES/WGS is currently limited and still 
developing.47,48,57 Providers were concerned that disclosure of 
actionable SF would warrant treatment or surveillance that may 
be harmful in itself or expensive.45 It may not always be clear 
how follow-up might be funded, particularly in insurance-
based health-care systems.48,57
Literacy.  Providers were often concerned that WES/WGS 
recipients do not always appreciate the implications of SF and 
may not be adequately informed to make decisions.45,47,48,60 
WES/WGS providers who have consented patients to WES/
WGS considered that participants’ lack of experience with 
the conditions related to SF complicates decision making.61 
Providers felt that recipients’ apparent enthusiasm for a wide 
range of SF—often wider than most programs currently offer—
may result from incomplete understanding of the implications 
of SF.47 Studies did report highly variable knowledge of WES/
WGS among WES/WGS recipients, both potential and 
actual,26,27,33,35,43,44,56 and providers’ own understanding of SF 
was highly variable and sometimes insecure,13,50,55,58,62,63 with 
implications for informed consent provision.
Pretest processes.  Stakeholder groups, across many studies, 
felt strongly that disclosure of SF should be guided by decisions 
made during consent.24,34,45,58,60,64,65 To optimize informed 
decision making, stakeholders in both groups felt that pretest 
discussions should supplement written information.24,49,64 Most 
providers felt that these discussions should include SF, whereas 
others variably included which SF would be reported, false-
positive/negative results, changing the interpretation of variants, 
family, and the potential for anxiety.54,61,62 Discussions are very 
context-dependent and should be flexible and tailored to the 
recipient.45,47,54,56,61 Very recent studies of HCPs’ experiences 
with WES/WGS counseling highlighted often-unrealistic 
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recipient expectations and the need to counteract this.43,56,61 
The length of time required to achieve informed consent was 
seen as burdensome for providers and recipients,56,61 but some 
practitioners described increasing confidence in efficiently and 
effectively obtaining informed consent with experience.45,61 
Actual WES/WGS recipients and HCPs who have consented 
them acknowledged recipient difficulty in thinking about SF 
during consent discussions when they are preoccupied by their 
primary health condition.23,61 Despite this, one qualitative study 
involving actual WES/WGS recipients found little support for 
a second consent process after the report of primary findings.23
Posttest processes.  Members of all stakeholder groups stressed 
the importance of genetic counseling at disclosure of results. 
Face-to-face meetings with a professional who has knowledge 
about genetics and the implications of SF were seen as essential 
by WES/WGS recipients27,32,49 and providers.47,49,51,58 WES/WGS 
providers felt that disclosure discussions should take disease 
burden into account34 and should be tailored to the participant, 
both in content and timing.45,54,62 A quantitative study exploring 
counseling experience for WES/WGS found that although both 
varied greatly in length, posttest discussions often lasted longer 
than pretest discussions.62 WES/WGS recipients also believed 
that a plan of action for clinical follow-up should be discussed 
at the point of disclosure,24,30 and some envisaged a need for 
ongoing support.30 Some HCPs felt they would not be able 
to provide psychosocial support themselves and would also 
require support from specialists specific to the SF disclosed.43,63
Family.  Relatives are considered important in the management 
of SF and a crucial component of informed consent and SF 
disclosure.25,34,35,42,47,57 Some studies of providers highlighted 
difficulties with family-based recruitment and consenting,54,56 
and several studies echoed issues well described in genetics 
regarding confidentiality and the right not to know.32,42,47,49,64,65 
Some recipients cited family as motivation to receive SF and, 
particularly for healthy individuals, for initial participation 
in WES/WGS.25,34,40,41,48 Stakeholders across all groups are, 
in principle, willing to share their personal WES/WGS 
results.26,27,30,32,34,35,40,44–46,54,65 However, despite wanting SF 
themselves, some recipients might filter SF information as 
follows: sharing only actionable findings,26,27,49,65 making 
decisions about impact on individual relatives,27 waiting 
until asked about results,45 or being selective about which 
relatives to tell.26 One study raised the potential for parents 
to experience guilt about the implied risk of an SF to 
descendants.46
Rights and responsibility.  The concepts of rights and 
responsibilities are strongly represented across the included 
studies. Potential WES/WGS recipients stressed the importance 
of autonomy—the right to choose which SF (if any) they 
should receive.24,26,27,30,32,39,41,46,49 These stakeholders also 
expressed a strong sense of ownership and desire for control 
over their genetic information.24,26,27,30,36,41,46,48,49 This sense of 
proprietorship even extended to family genetic data, with some 
stakeholders expressing a right to be informed about genetic 
findings present in relatives.26,42,47 Perceived rights to “their” 
information appeared to be an important driver for potential 
recipients’ desire for a wide range of SF: there were strong 
objections to paternalism, or WES/WGS providers withholding 
or interpreting information on recipients’ behalf, in an effort to 
decide what is in their best interest.13,24,49
WGS providers agreed that participant autonomy was 
important, and most believed they would respect consent 
decisions with respect to the SF offered.13,27,30,42,45,47,49–51,54,55,58–60,64 
However, providers also perceive a strong sense of responsibil-
ity to recipients and believe that fulfilling this requires careful 
consideration about the utility of SF, often supporting a mul-
tidisciplinary approach to reach optimally informed disclo-
sure decisions.42,47,58,60 Providers in one study raised concerns 
about determining the significance of individual variants, list-
ing various sources of evidence (e.g., allele frequency, segre-
gation data, and previous reports) contributing to judgments, 
but that, ultimately, pathogenicity is often very difficult to 
assess.57,60 Providers felt this uncertainty would be challenging 
for patients to understand.48 Responsibility was also discussed 
with respect to SF management in general, with most groups 
agreeing that responsibility must be shared between all par-
ties24,26,49,50,57,58,60,63,65: HCPs, WES/WGS recipients,24,41,48,57,60 par-
ents,26,32,36,46,49 and laboratory professionals.50,58
In some studies, providers’ views were derived from experi-
ence with other genetic testing methods (such as prenatal or 
microarray-based testing) and note patients’ mixed and com-
plex reactions, unanticipated before testing, to receiving SF.47,50 
When WES/WGS recipients choose not to receive SF, some 
providers foresee a possible conflict between their profes-
sional responsibility in the duty to warn and respecting par-
ticipant autonomy.50,58,60 Some providers considered over-riding 
a decision not to receive SF if a clinically significant SF were 
found.13,42,47,48,50,54
Time. The idea of “duration of responsibility” recurred in various 
studies and stakeholder groups. Most WES/WGS providers 
supported gaining consent for re-interrogation of data and 
re-contact as new interpretations become available.13,32,54,60 
Potential recipients also felt that they should be re-contacted 
as interpretation changes or information becomes relevant, 
such as approaching the age at which a screening program 
might begin.29,32,39,46 However, there was no consensus as to 
who should initiate re-contact; some felt WES/WGS recipients 
should share this responsibility with providers.49,60 WES/WGS 
providers did consider that the duration of responsibility might 
differ depending on whether the program had a research or 
clinical focus: researchers felt that their responsibility would 
have to be restricted to the duration of funding65 and clearly 
communicated during the consent process.55 Some providers 
had concerns that the loss of connection after the completion 
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of a research study would complicate re-contact in a research 
setting.54
Policies and practices.  Stakeholders in some studies 
appreciated the logistic complexity of SF management, and 
that it is further complicated by incomplete understanding 
of significance for current and/or future health.23,47 Some 
raised concerns about the quality and accuracy—in terms of 
both analytical and clinical validity—of current sequencing 
technologies and analysis39,48,55,57 and worried that there are 
currently insufficient resources to accurately analyze the data 
and return it in a meaningful way.49 Many HCPs and genomics 
researchers were unaware of definitive local procedures, policies, 
or expectations regarding WES/WGS and SF.47,50,53,57,63,65 WES/
WGS providers discussed various options for SF management. 
There was support for the ACMG “minimal gene list,”51,58,59 
“binning” or categorizing of variants,48,60 an advisory board or 
multidisciplinary team,58,60 and for minimizing the generation 
of SF at the present time.47,49,64,65 However, there was no 
consensus on the best approach, and other study participants 
voiced arguments against each of these options.47,48,58–60 There 
was agreement that guidelines should be flexible, allowing for 
varying levels of expertise in a highly dynamic field.42,46,47,50
Synthesis
There is a spectrum of views about SF management, ranging 
from generating and disclosing a wide range of SF to intention-
ally minimizing their occurrence. Figure 2 offers a theoretical 
framework that illustrates the balancing of factors that influence 
stakeholder preferences around SF disclosure in WES/WGS.
Potential WES/WGS recipients’ views frequently fall to the 
less conservative end of the spectrum, favoring disclosure of a 
wide range of SF often including nonmedical findings as well 
as those that have health implications but are not medically 
actionable. This prompts questions about recipients’ under-
standing of genomic complexity and difficulties distinguishing 
“normal” variation from that which may be clinically signifi-
cant. Preference for SF among recipients appears to be strongly 
associated with a sense of rights, such as ownership (the right to 
their personal information) and autonomy (the right to choose 
what information they receive). Potential recipients feel that 
they are entitled to access their genetic results if they choose to 
receive them and perceive genomics/health-care professionals’ 
deliberations and restriction of SF as paternalistic. This review 
highlights evidence from qualitative studies indicating that 
recipients’ stated preference for SF may be an initial response 
that might be subject to change with discussion and reflection 
on possible implications.
Providers’ views are also informed by their professional 
responsibility to WES/WGS recipients. This sense of responsi-
bility manifests in the views about SF; concerned about logistics, 
including the analysis process and interpretation of variants, 
and uncertainty about how to handle uncertain results, pro-
viders expressed concerns about causing psychological harm 
by returning SF. Some studies involving HCPs contain quotes 
suggesting that they have personal anxieties about disclosing 
findings of potentially high impact57,60 or are concerned about 
the range of possible SF,63 raising a possible need for further 
training and support for HCPs actively disclosing SF.
Studies involving parents highlighted distinct and instructive 
views.26,30,32,35,36 As with other potential recipients, parents wish 
to receive a wide range of SF but demonstrate intentions to filter 
the information they tell their children, even when they are no 
longer minors. This suggests that parents balance a perceived 
right to their (child’s) genomic information with the respon-
sibility to protect their children from any potential harm—-
analogous to the balancing of benefits and harms exhibited by 
HCPs. Also of interest, patients with cancer diagnoses were 
less likely to want a wide range of SF, preferring to receive only 
clinically actionable findings.27,29,35 This may stem from a con-
textualized understanding of the implications of genetic results 
for personal health care, based on their experience with genetic 
testing and illness.
Some studies postulate that greater or lesser knowledge of 
WES/WGS might account for the differing views. However, 
many of those who provided insightful responses often reported 
low “knowledge” of sequencing technology. These individuals, 
however, frequently drew on their experience with genetic dis-
ease.27,29,41 For instance, in a qualitative study of patients with 
Lynch syndrome, only one participant had ever heard of WES/
WGS, yet many demonstrated a very nuanced appreciation of 
findings from WES/WGS.27 Across the studies, for participants 
who had experience with genetic illness and prior genetic coun-
seling and testing, this informed their understanding of possible 
results and they expressed tolerance for uncertainty. Members 
of these groups had a broad understanding of (medical) genet-
ics but not necessarily of sequencing technologies, and they 
were more likely to make distinctions between the kinds of SF 
they wished to receive. Together with genetics HCPs, WES/
WGS recipients with experience with genetic testing for rare 
Figure 2 theoretical framework illustrating factors influencing 
stakeholder preferences regarding disclosure of secondary findings 
in whole-exome and whole-genome sequencing.
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diseases or cancer also appreciated that the relevance of SF is 
dependent on time and circumstances.27,29,41
diSCUSSiOn
We have presented a systematic review and synthesis of the 
range of perspectives on secondary findings in WES/WGS. 
The review found that there is agreement across stakehold-
ers regarding the importance of patient autonomy in the 
management of SF. Which results should be generated and 
made available, however, is less clear. Participants gener-
ally support the return of “actionable” findings; however, 
definitions of “actionability” varied. Stakeholders generally 
agreed that SF for life-threatening diseases for which treat-
ment or surveillance is available and actionable should be 
offered. However, study participants variously included 
management, lifestyle modifications, and personal utility 
as aspects of SF “actionability.” Of note, a recent systematic 
review found no evidence that genetic risk estimates moti-
vate behavioral changes.66 Nonetheless, this variability high-
lights the context dependency of “actionability” in SF and 
poses a challenge to reaching a consensus on SF disclosure 
and management.
Despite differing views on what to disclose, stakeholders 
agreed on the concept of shared responsibility regarding SF 
disclosure. Because there is widespread agreement that SF 
decisions at the time of WES/WGS consent should deter-
mine which results are disclosed, it is incumbent on pro-
viders to ensure that WES/WGS recipients are prepared for 
results, including implications and limitations. Education 
and greater understanding of the potential and limitations of 
WES/WGS and SF would support informed decision mak-
ing and narrow the gap between recipients’ expectations 
and the current situation in which providers consider which 
SF are useful to generate based on existing knowledge and 
resources. This remains a subject of debate67 and is likely to 
remain so for the foreseeable future as data accumulate on 
variant pathogenicity.
Exactly what is required to reach a sufficient level of under-
standing about SF is not yet clear. It appears that genetic literacy 
does inform stakeholder decisions and that greater under-
standing often results in greater circumspection about SF. This 
“literacy,” however, appears to be less so technical knowledge 
of WES/WGS and more so qualitative understanding of the 
implications and limitations. In two recent studies that explore 
HCP experiences consenting WES/WGS recipients, providers 
acknowledged a shift in the content of their pretest discussions 
with experience, that is, moving away from discussing fine 
details of WES/WGS to focusing on the potential results and 
implications.42,61 It will be important for future studies to find 
ways of measuring what is important to understand to make 
informed decisions about SF.
It is worth noting the methodologies used by the primary 
studies. The current perception in WES/WGS practice that 
recipients want a wide range of SF is informed by survey studies; 
presented with a tick box, recipients elect in favor of receiving all 
SF they are offered (and might wish for more than offered).25,33 
However, qualitative studies highlight how recipients might 
alter these initial thoughts later or when they have the chance 
to reflect on and discuss possible implications. If consent mir-
rors survey studies in the sense that unidirectional imparting of 
information is followed by a “tick box” answer, then individuals 
can be expected to elect in favor of receiving SF. The inclusion of 
qualitative and quantitative studies in this review allows infor-
mative comparison and suggests that for recipients to reach a 
holistic understanding of the implications of WES/WGS and 
SF, a bidirectional interaction akin to qualitative methodologies 
is more likely to facilitate informed decision making. Included 
studies suggest that participant reflection and discussion can 
result in greater appreciation of the potential implications and 
consequences of SF; this is consistent with the fact that fewer 
people participate in predictive genetic testing, even for condi-
tions for which intervention is available, than express a hypo-
thetical intent.68 It is likely that a one-time decision about SF 
may not represent WES/WGS recipients’ changing views and 
circumstances, and more dynamic forms of consent should be 
considered.
Stakeholder preference is, by no means, the only factor 
requiring consideration in policy development regarding SF; 
further empirical research collecting data on returned SF is 
essential to inform stakeholder views on clinical utility and 
impacts in the broadest sense on WES/WGS recipients, health-
care systems, and society. Impacts on resources for informed 
consent and genetic counseling in WES/WGS, for analysis and 
validation, and for clinical screening and management after 
disclosure need to be assessed as part of setting overall health-
care priorities.
WGS/WES initiatives are taking diverse approaches toward 
the issue of secondary findings in WES/WGS. This diversity, 
per se, represents the views of providers and the project-level 
discussions that have contributed to policy. It is likely that the 
ACMG list has influenced initiatives that have begun since its 
publication, with large-scale programs such as the UK 100,000 
Genomes Project offering opportunistic screening of a (more 
limited) gene list in addition to recessive and X-linked carrier 
status for couples and female participants, respectively. Some 
protocols offer an even wider range of SF,69 whereas others avoid 
SF generation.70 There is a possibility that WES/WGS recipients 
and the public will view such policy-level decisions as paternal-
istic, and it will be important for programs to be  flexible and 
responsive to research findings.
Study limitations
No studies report on experiences with disclosure or receipt of 
secondary genomic findings. Both WES/WGS recipients and 
providers are diverse in terms of experiences with genetic 
illness and testing or professional experience with patients 
and/or WES/WGS. Although studies of participants with 
direct WES/WGS experience, particularly recipients, add 
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qualitatively to this dataset, we found no evidence from our 
analysis that WES/WGS experience alters the thematic areas 
presented here.
Discussions of return of results often include SF without ref-
erencing them explicitly. We have used broad search terms to 
capture variable nomenclature used by primary studies and 
a thorough screening process; however, because we excluded 
non-English studies and articles without full text, and as a result 
of the variation in terminology around SF, it is possible that we 
missed some relevant studies.
The included studies predominantly present the perspectives 
of whites in the United States. Two studies that included stake-
holders from other groups40,47 presented additional data and 
indicated that findings to date might not be comprehensive and 
representative of diverse groups.
Conclusions and implications for practice
In this systematic review, we have shown that the views of 
both WES/WGS providers and recipients with respect to 
returning SF exist on a spectrum. We suggest that a nuanced 
understanding of the implications of WES/WGS and poten-
tial findings—rather than technical knowledge—might better 
inform the decision making in the management of SF. Views 
and preferences of providers and recipients are not fixed; they 
are continually informed by experience, discussion, time, and 
circumstances. Pretest discussions with trained practitioners 
are therefore essential to inform participant decisions. We rec-
ommend the following:
1. Further research into:
i. The impacts of SF when returned at the individual and 
family levels and on health-care systems.
ii. Stakeholders’ appreciation for the implications of 
WES/WGS and SF, what knowledge is required to 
make informed decisions about SF, how to assess this, 
and how they relate to decisions to receive or disclose 
SF.
iii. Wider perspectives on SF and WES/WGS, particu-
larly among non-Americans and cultural and ethnic 
minorities, and individuals undergoing WES/WGS, 
including parents.
2. Evidence-based training and education for HCPs provid-
ing informed consent.
3. Training and support for HCPs returning high-impact SF 
from WES/WGS.
4. Clarifying expectations and guidelines for translational 
genomics research.
5. Enhancing communication and apportioning of respon-
sibility between those involved in WES/WGS: HCPs, 
laboratory professionals, and WES/WGS recipients.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim
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